Literature DB >> 16849899

Spironolactone: an old friend rediscovered.

Domenic A Sica.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16849899      PMCID: PMC8109308          DOI: 10.1111/j.1524-6175.2006.05155.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  19 in total

Review 1.  Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade.

Authors:  Akira Nishiyama; Youichi Abe
Journal:  J Pharmacol Sci       Date:  2006-01-06       Impact factor: 3.337

2.  Clinical implications of primary aldosteronism with resistant hypertension.

Authors:  E L Bravo; F M Fouad-Tarazi; R C Tarazi; M Pohl; R W Gifford; D G Vidt
Journal:  Hypertension       Date:  1988-02       Impact factor: 10.190

3.  Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.

Authors:  Atsuhisa Sato; Koichi Hayashi; Takao Saruta
Journal:  Am J Hypertens       Date:  2005-01       Impact factor: 2.689

4.  A double-blind comparison of spironolactone and hydrochlorothiazide in hypertensive patients treated with metoprolol.

Authors:  B Lavenius; L Hansson
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1982-06

5.  Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.

Authors:  C S Barr; C C Lang; J Hanson; M Arnott; N Kennedy; A D Struthers
Journal:  Am J Cardiol       Date:  1995-12-15       Impact factor: 2.778

Review 6.  Pharmacotherapy in congestive heart failure: aldosterone receptor antagonism: interface with hyperkalemia in heart failure.

Authors:  Domenic A Sica; Michael Hess
Journal:  Congest Heart Fail       Date:  2004 Sep-Oct

7.  Efficacy of low-dose spironolactone in subjects with resistant hypertension.

Authors:  Mari Konishi Nishizaka; Mohammad Amin Zaman; David A Calhoun
Journal:  Am J Hypertens       Date:  2003-11       Impact factor: 2.689

8.  Hydrochlorothiazide and spironolactone in hypertension.

Authors:  G Schrijver; M H Weinberger
Journal:  Clin Pharmacol Ther       Date:  1979-01       Impact factor: 6.875

9.  Diuretic treatment of resistant hypertension.

Authors:  L E Ramsay; J H Silas; S Freestone
Journal:  Br Med J       Date:  1980-10-25

10.  Eplerenone: a new aldosterone receptor antagonist--are the FDAs restrictions appropriate?

Authors:  D A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Nov-Dec       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.